Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Mayo Clinic- Jacksonville

Jacksonville, Florida 32224, United StatesNot linked to an institution yet

90running trials
35closed trials

The trials here

What the 125 trials at this site are about, from their registry records.

Conditions: Lung cancer14 trials
Sarcoma11 trials
Alzheimer disease9 trials
Childhood cancers9 trials
Chronic lymphocytic leukaemia8 trials
Prostate cancer8 trials
Ovarian cancer7 trials
Acute myeloid leukaemia6 trials
Colorectal cancer6 trials
Gastric and oesophageal cancer6 trials
Head and neck cancer6 trials
Multiple myeloma6 trials
and 46 more
Phase: Phase 336 trials
Phase 224 trials
Phase 1/217 trials
Phase 116 trials
Phase 2/33 trials
Phase 42 trials
Status: Recruiting45 trials
Active, not recruiting37 trials
Completed25 trials
Terminated8 trials
Enrolling by invitation4 trials
Not yet recruiting4 trials
Withdrawn2 trials
Lead sponsor: Novartis Pharmaceuticals9 trials
Regeneron Pharmaceuticals4 trials
University of Southern California4 trials
BeOne Medicines3 trials
USWM CT, LLC3 trials
and 86 more

Running trials

Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264· Phase 3· CSL Behring· Source
Contact: Trial Registration Coordinator
Recruiting
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07771465· Phase 3· Kardigan, Inc.· Source
Contact: Kardigan Clinical Trial Team
Recruiting
Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?
NCT07454733· Trustees of Dartmouth College· Source
Contact: Björn Oskarsson, MD
Recruiting
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
NCT07671911· Phase 3· Trevi Therapeutics· Source
Contact: Paula Buckley
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
NCT07428616· Phase 2· Exelixis· Source
Contact: Exelixis Clinical Trials
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290· Phase 2· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177· Phase 2· Novartis Pharmaceuticals· Source
Contact: Jarell C Hughes
Recruiting
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
NCT07051707· Nuvaira, Inc.· Source
Contact: John Hazimouratides
Recruiting
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723· Phase 2/3· Kardigan, Inc.· Source
Contact: Kardigan Clinical Trial Team
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190· Phase 3· IDEAYA Biosciences· Source
Contact: Bently Doonan, MD Principal Investigator
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
NCT07142291· Phase 2· PhenoNet, Inc.· Source
Contact: David R Elmaleh, PhD
Active, not recruiting
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037· Phase 2· Vertex Pharmaceuticals Incorporated· Source
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT07217704· Phase 3· SOFIE· Source
Contact: Chyann Moore
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591· Phase 1/2· Tango Therapeutics, Inc.· Source
Contact: Hani Babiker, MD (principal investigator)
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752· Phase 3· Novartis Pharmaceuticals· Source
Contact: Minoshka Chaparro Gardner
Recruiting
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
NCT06787612· Phase 2· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544· Phase 1/2· Tango Therapeutics, Inc.· Source
Contact: Hani Babiker, MD (principal investigator)
Active, not recruiting
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
NCT06868290· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
NCT06736418· Phase 1· Abdera Therapeutics Inc.· Source
Recruiting
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06720987· Phase 1· Kumquat Biosciences Inc.· Source
Contact: Kumquat Clinical Development
Active, not recruiting
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316· Phase 1/2· Cogent Biosciences, Inc.· Source
Enrolling by invitation
Utility of Random Biopsies in Patients With Inflammatory Bowel Disease
NCT06560021· Abramson Cancer Center at Penn Medicine· Source
Active, not recruiting
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985· Phase 2· Coherus Oncology, Inc.· Source
Active, not recruiting
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572· Vertex Pharmaceuticals Incorporated· Source
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192· Phase 1· Novartis Pharmaceuticals· Source
Contact: Alberta Lalljie
Active, not recruiting
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564· Phase 2· Incyte Corporation· Source
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801· Phase 3· Gossamer Bio USA, Inc.· Source
Contact: GB002 Inc.
Recruiting
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
NCT06362252· Phase 1/2· Daiichi Sankyo· Source
Contact: Principal Investigator
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source
Contact: John Mei
Active, not recruiting
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
NCT06260709· Phase 2· Novo Nordisk A/S· Source
Recruiting
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059· Phase 2· Cumberland Pharmaceuticals· Source
Contact: Jhozia Duncan
Active, not recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299· Phase 1· Kyowa Kirin Co., Ltd.· Source
Active, not recruiting
A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study
NCT07045103· Invenio Imaging Inc.· Source
Recruiting
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT06056830· Phase 3· Clarity Pharmaceuticals Ltd· Source
Contact: Ephraim Parent, MD
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629· Phase 3· Intellia Therapeutics· Source
Contact: Trial Manager at Intellia
Active, not recruiting
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385· Phase 2· Center for International Blood and Marrow Transplant Research· Source
Active, not recruiting
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740· Phase 1· TORL Biotherapeutics, LLC· Source
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Clinical Trials Office - All Mayo Clinic Locations
Enrolling by invitation
Alzheimer's Plasma Extension
NCT06416072· University of Southern California· Source
Active, not recruiting
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06088290· Phase 3· PharmaMar· Source
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941· Phase 4· Novartis Pharmaceuticals· Source
Contact: Winston Tan (principal investigator)
Recruiting
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
NCT05919511· Incyte Corporation· Source
Recruiting
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
NCT05735184· Phase 1· Kura Oncology, Inc.· Source
Contact: Clinical Trials Referral Office
Active, not recruiting
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656· Phase 2· Cognition Therapeutics· Source

Showing 50 of 90.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Terminated
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source
Completed
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
NCT05639751· Phase 1· Prelude Therapeutics Incorporated· Source
Completed
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
NCT05593328· Phase 2· Cardiff Oncology· Source
Completed
Study of DF9001 in Patients With Advanced Solid Tumors
NCT05597839· Phase 1/2· Dragonfly Therapeutics· Source
Completed
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05287113· Phase 2· Incyte Biosciences International Sàrl· Source
Completed
A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis
NCT05442047· Phase 2· Novo Nordisk A/S· Source
Terminated
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
NCT05355753· Phase 1· C4 Therapeutics, Inc.· Source
Completed
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
NCT03961945· Mayo Clinic· Source
Completed
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
NCT03776071· Phase 3· Denovo Biopharma LLC· Source
Completed
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
NCT04641871· Phase 1· Symphogen A/S· Source
Completed
Phase 1 Study of Oral TP-1454
NCT04328740· Phase 1· Sumitomo Pharma America, Inc.· Source
Terminated
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
NCT04266301· Phase 3· Novartis Pharmaceuticals· Source
Terminated
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
NCT04017130· Phase 1· Molecular Templates, Inc.· Source
Completed
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
NCT06703346· Phase 2· USWM CT, LLC· Source
Completed
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
NCT05993299· Phase 2· USWM, LLC (dba US WorldMeds)· Source
Completed
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
NCT04209855· Phase 3· AbbVie· Source
Terminated
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
NCT04204941· Phase 1· Epizyme, Inc.· Source
Completed
A Trial Evaluating TG4050 in Ovarian Carcinoma.
NCT03839524· Phase 1· Transgene· Source
Completed
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
NCT04082364· Phase 2/3· MacroGenics· Source
Completed
TRC-PAD Program: In-Clinic Trial-Ready Cohort
NCT04004767· University of Southern California· Source
Completed
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
NCT03570892· Phase 3· Novartis Pharmaceuticals· Source
Terminated
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
NCT03893682· Phase 1· Aptose Biosciences Inc.· Source
Completed
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)
NCT03657342· Phase 3· Zambon SpA· Source
Completed
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
NCT03656926· Phase 3· Zambon SpA· Source
Completed
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
NCT03740529· Phase 1/2· Loxo Oncology, Inc.· Source
Recruiting
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
NCT03016819· Phase 3· Advenchen Laboratories, LLC· Source
Contact: Shiying Clinical Trial Manager
Completed
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
NCT03037385· Phase 1/2· Hoffmann-La Roche· Source
Completed
Alzheimer's Disease Neuroimaging Initiative 3
NCT02854033· University of Southern California· Source
Terminated
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
NCT02841540· Phase 1· Hemavant Sciences GmbH· Source
Completed
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
NCT02601950· Phase 2· Epizyme, Inc.· Source
Completed
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
NCT02158858· Phase 1/2· Constellation Pharmaceuticals· Source
Recruiting
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134· Boston Scientific Corporation· Source
Contact: Heleen Scholtes
Recruiting
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839· Phase 1· Institut de Recherches Internationales Servier· Source
Contact: Institut de Recherches Internationales Servier Clinical Studies Department
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545· Center for International Blood and Marrow Transplant Research· Source
Contact: Elizabeth Fosberg, B.A.
Completed
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
NCT00309985· Phase 3· ECOG-ACRIN Cancer Research Group· Source

Site data: ClinicalTrials.govUpdated 14 Nov 2026

Report an error

Under construction, not live – Mayo Clinic- Jacksonville: trial site – Frontlight Research